Wednesday 14th February 2018 |
Text too small? |
Ralph Norris will step down as chairman of Fletcher Building after the company took a further $486 million provision for project losses at its Building + Interiors unit and said 14 of the unit's 73 projects, worth $2.3 billion, are loss-making or 'on watch'.
Fletcher shares are due to resume trading this morning after being halted last week for the announcement. The projected 2018 loss for B+I has been widened to $660 million on an earnings before interest and tax basis from a previous estimate of $160 million, while guidance for group ebit excluding B+I was reiterated at $680 million to $720 million.
Norris said he will step down at the 2018 annual meeting toward the end of the year. Chief executive Ross Taylor, who conducted a review of Fletcher's strategy after taking the job last November, said the new provisions "was informed by a review of 16 B+I projects, accounting for about 90 percent of the construction backlog."
B+I was now focused "on project delivery only" and was "ceasing all bidding on vertical construction projects in New Zealand," Taylor said. "While our broader construction businesses continue to benefit from favourable market conditions and strong growth, the B+I sector remains characterised by high contract risk and low margins. Unless these dynamics change we will no longer work in this sector."
A $20 million restructuring provision to exit B+I has also been recognised, with key resources to be redeployed to other construction division businesses as B+I projects are completed.
Fletcher said it has obtained a waiver from its commercial banking syndicate after breaches the terms of its loans. Taylor said the strength of Fletcher's remaining business and the phasing of the cash impact of the B+I provisions "meant the company remains well capitalised and solvent."
Fletcher shares last traded at $7.77 and have tumbled 23 percent in the past 12 months.
(BusinessDesk)
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors